News
Feed
Events
Feed
News
+ Events
Feed

RedHill Biopharma Ltd.

  • ISIN IL0011223810
  • Land Israel

Aktuelle News

23 Juni 2022

13:05 Corporate

RedHill Biopharma Ltd.

Corporate

RedHill Biopharma veröffentlicht Highlights aus Q1/2022: Im Plan zu einem positiven operativen Cashflow in H2/22

11 April 2022

15:49 Corporate

RedHill Biopharma Ltd.

Corporate

RedHill gibt effektive Hemmung der Omikron-Variante durch seinen oralen COVID-19-Wirkstoffkandidaten Opaganib in vitro bekannt

15:21 Corporate

RedHill Biopharma Ltd.

Corporate

RedHill gibt effektive in vitro-Hemmung der Omikron-Variante durch seinen oralen COVID-19-Wirkstoffkandidat Opaganib in vivo bekannt

15 März 2022

14:08 Corporate

RedHill Biopharma Ltd.

Corporate

​​​​​​​RedHill und Kukbo unterzeichnen Lizenzvereinbarung für oral verabreichtes Opaganib zur Behandlung von COVID-19 in Südkorea

1 März 2022

15:03 Corporate

RedHill Biopharma Ltd.

Corporate

RedHill gibt positive Phase-2-Studienergebnisse mit oral verabreichtem RHB-107 an nicht hospitalisierten COVID-19-Patienten bekannt

17 Februar 2022

15:34 Corporate

RedHill Biopharma Ltd.

Corporate

RedHill Biopharma meldet Rekord-Quartalsumsatz und erreicht zum ersten Mal kommerzielle Gewinnzone

7 Februar 2022

16:25 Corporate

RedHill Biopharma Ltd.

Corporate

RedHill Biopharmas orales Opaganib senkt in Kombination mit Remdesivir und Kortikosteroiden die Sterblichkeitsrate bei schwerer COVID-19 um 70 %

13 Januar 2022

16:45 Corporate

RedHill Biopharma Ltd.

Corporate

Oral verabreichtes Opaganib von RedHill Biopharma zeigt signifikante Verbesserung der Viruselimination in Phase-2/3-Studie bei schwer erkrankten, hospitalisierten COVID-19-Patienten

13 November 2017

14:08 Corporate EN

RedHill Biopharma Ltd.

Corporate
EN

RedHill Biopharma Reports 2017 Third Quarter Financial Results

9 November 2017

13:27 Corporate EN

RedHill Biopharma Ltd.

Corporate
EN

RedHill Biopharma Announces Last Patient Enrolled in the Phase III Study with RHB-104 for Crohn’s Disease

2 November 2017

09:00 Corporate EN

RedHill Biopharma Ltd.

Corporate
EN

RedHill Biopharma and IntelGenx Submit New Drug Application to FDA for RIZAPORT(R) for Migraines

26 Oktober 2017

13:51 Corporate

RedHill Biopharma Ltd.

Corporate

RedHill Biopharma präsentiert auf der BIO-Europe 2017

20 Oktober 2017

14:12 Corporate EN

RedHill Biopharma Ltd.

Corporate
EN

RedHill Biopharma Receives FDA Orphan Drug Designation for MESUPRON for Pancreatic Cancer

3 Oktober 2017

14:19 Corporate EN

RedHill Biopharma Ltd.

Corporate
EN

RedHill Biopharma Announces Positive Top-Line Results from Phase II Study of BEKINDA(R) in Patients with Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)

2 Oktober 2017

13:30 Corporate EN

RedHill Biopharma Ltd.

Corporate
EN

RedHill Biopharma Accelerates RHB-104 Phase III Study in Crohn’s Disease with Top-Line Results Expected Mid-2018

18 September 2017

14:46 Corporate

RedHill Biopharma Ltd.

Corporate

RedHill Biopharma Receives Notice of Allowance for a New U.S. Patent Covering its Combination Therapy for Hard-to-Treat Cancers

13 September 2017

14:01 Corporate EN

RedHill Biopharma Ltd.

Corporate
EN

RedHill Biopharma Ltd.: RedHill Biopharma Initiates Promotion of Esomeprazole Strontium Delayed-Release Capsules 49.3 mg in the U.S

17 August 2017

14:57 Corporate EN

RedHill Biopharma Ltd.

Corporate
EN

RedHill Biopharma Announces U.S. Commercialization Agreement for FDA-Approved GI Product Esomeprazole Strontium Delayed-Release Capsules :

10 August 2017

17:22 Corporate EN

RedHill Biopharma Ltd.

Corporate
EN

RedHill Biopharma Provides 2017 Semi-Annual Business Update

31 Juli 2017

14:44 Corporate EN

RedHill Biopharma Ltd.

Corporate
EN

RedHill Biopharma Announces Unanimous Positive DSMB Recommendation for Continuation of the Phase III Study with RHB-104 for Crohn’s Disease

25 Juli 2017

14:29 Corporate EN

RedHill Biopharma Ltd.

Corporate
EN

RedHill Biopharma Reports 2017 Second Quarter Financial Results

17 Juli 2017

15:56 Corporate EN

RedHill Biopharma Ltd.

Corporate
EN

RedHill Biopharma Announces Last Patient Visit in BEKINDA(R) Phase II Study for IBS-D

12 Juli 2017

14:08 Corporate EN

RedHill Biopharma Ltd.

Corporate
EN

RedHill Biopharma Announces Expected Timeline for DSMB meeting and Provides Updated on Enrollment in the RHB-104 Phase III Study for Crohn’s Disease

15 Juni 2017

15:30 Corporate EN

RedHill Biopharma Ltd.

Corporate
EN

RedHill Biopharma Announces Confirmatory Phase III Study Initiated with RHB-105 (TALICIA(TM)) for H. pylori Infection

14 Juni 2017

15:00 Corporate EN

RedHill Biopharma Ltd.

Corporate
EN

RedHill Biopharma Announces Successful Phase III Top-Line Results with BEKINDA(R) for Acute Gastroenteritis

13 Juni 2017

14:26 Corporate EN

RedHill Biopharma Ltd.

Corporate
EN

RedHill Biopharma Initiates Promotion of Donnatal(R) and EnteraGam(R) in the U.S.

3 Mai 2017

12:09 Corporate EN

RedHill Biopharma Ltd.

Corporate
EN

RedHill Biopharma Reports 2017 First Quarter Financial Results

24 April 2017

16:34 Corporate EN

RedHill Biopharma Ltd.

Corporate
EN

RedHill Biopharma Announces Enrollment of Last Patient in the BEKINDA(R) Phase II Study for IBS-D

18 April 2017

15:29 Corporate EN

RedHill Biopharma Ltd.

Corporate
EN

RedHill Biopharma Receives Notice of Allowance for Two Additional U.S. Patents Covering BEKINDA(R)

5 April 2017

14:00 Corporate EN

RedHill Biopharma Ltd.

Corporate
EN

RedHill Biopharma Announces Exclusive U.S. License from Entera Health for Commercial GI Product EnteraGam(R)

Anstehende Events

Keine Events gefunden